ICML

NTT Research Funds New Program with Harvard Center for Brain Science

Retrieved on: 
Thursday, April 11, 2024
Software, Research, Technology, Artificial Intelligence, University, Health Technology, Education, Science, Biotechnology, Neurology, Other Science, Health, Harvard University, Physics, Bias, ICML, AI, JRA, NTT, CIM, Behavior, MIT, Brain, University of Notre Dame, Statistics, Princeton University, CBS, Cornell University, Invention, Mouse, ICLR, Travel, Neuroscience, Nippon Telegraph and Telephone, Liquid, Cognitive science, Ames Research Center, Swinburne University of Technology, Psychology, Fellow, Organization, Stanford University, Electricity, Applied Physics Letters, PHI, Reddy

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that the NTT Research Foundation, a 501(c)3 organization, has made a gift to establish the Harvard University Center for Brain Science (CBS)-NTT Fellowship Program in the new field of Physics of Intelligence.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that the NTT Research Foundation, a 501(c)3 organization, has made a gift to establish the Harvard University Center for Brain Science (CBS)-NTT Fellowship Program in the new field of Physics of Intelligence.
  • This new program will amplify themes that have emerged through a pre-existing relationship between Harvard CBS and the NTT Research Physics & Informatics (PHI) Lab .
  • Under a 2021 joint research agreement , the two organizations undertook shared research into natural and artificial intelligence.
  • Now an assistant professor at Princeton University, Reddy also published a notable paper on “ discontinuous learning .”
    “We are thrilled to support the Harvard Center for Brain Science at the dawn of the Physics of Intelligence,” NTT Research President and CEO Kazu Gomi said.

AITRICS to Participate in HIMSS USA 2024

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Conference, Unexpected, Risk, Patient, Hospital, Artificial intelligence, Acquisition, HIMSS, CPR, Exhibition, ICML, Machine learning, Mortality, ICU

SEOUL, South Korea, March 12, 2024 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology announced on the 11th that it would participate in the 'HIMSS Global Health Conference & Exhibition' (2024 HIMSS USA) held in Orlando, Florida, USA from March 11 to 15.

Key Points: 
  • SEOUL, South Korea, March 12, 2024 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology announced on the 11th that it would participate in the 'HIMSS Global Health Conference & Exhibition' (2024 HIMSS USA) held in Orlando, Florida, USA from March 11 to 15.
  • The HIMSS Global Health Conference & Exhibition is the world's largest and most authoritative international event in the field of healthcare information and communication technology, organized by the Healthcare Information and Management Systems Society (HIMSS).
  • Over 1,100 companies from around the world will participate in this exhibition.
  • Furthermore, AITRICS would aim to facilitate business discussions with US healthcare professionals and continue to pursue additional collaborative research endeavors.

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Follicular lymphoma, Mantle cell lymphoma, Bristol Myers Squibb, ICML, MCL, Clinical trial, Lymphocytosis, Patient, New Drug Application, Shanda, Lymphoma, FDA, BMY, Priority review, Food, Society, MHLW, PDUFA, ASH, NHL, Chronic lymphocytic leukemia, Conference, Pharmaceutical industry

In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi).

Key Points: 
  • In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi).
  • The FDA has granted both applications Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 23, 2024 for Breyanzi in relapsed or refractory FL and May 31, 2024 for Breyanzi in relapsed or refractory MCL.
  • Japan's MHLW has also accepted Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for Breyanzi for the treatment of relapsed or refractory FL.
  • In both studies, Breyanzi demonstrated a consistent safety profile with no new safety signals reported.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, November 2, 2023
Research, Society for Hematology and Stem Cells, PIN, Second Half, PFS, Investment, News, SITC, Annual general meeting, Kinetics, ICML, Infection, CAR, International Conference on Afghanistan, London (2010), CD70, Society for Immunotherapy of Cancer, GAAP, Licensure, ORR, University, Cancer, Anti-CD19 immunotoxin, Therapy, Patient, Lymphoma, ASCO, B-cell lymphoma, Congress, Conference, Cytopenia, ASH, Immunotherapy, Dor, Cytokine release syndrome, Follicular lymphoma, Society, MD Anderson Cancer Center, Investigational New Drug, Kite Pharma, AACR, IND, Incidence, FC, American Society of Clinical Oncology, RCC, Poster, General counsel, Vaccine, Pharmaceutical industry

Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.

Key Points: 
  • Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.
  • Research and development expenses were $46.0 million for the third quarter of 2023, which includes $6.7 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $17.0 million for the third quarter of 2023, which includes $8.6 million of non-cash stock-based compensation expense.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, November 2, 2023
CAR, Kite Pharma, Malignancy, FC, International Conference on Nuclear Disarmament, Oslo, 2008, B-cell lymphoma, Safety, Research and development, American Society of Clinical Oncology, Conference, Chair, Society, Development, ASH, Risk, Allotransplantation, Follicular lymphoma, Annual general meeting, Kinetics, Cancer, University, ICML, H. Lee Moffitt Cancer Center & Research Institute, Immunotherapy, Therapy, MD Anderson Cancer Center, Investigator's brochure, ASCO, SAN, Pharmaceutical industry, Vaccine, Patient

“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.

Key Points: 
  • “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
  • Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
  • Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.

NTT Research PHI Lab Scientists Address Bias in AI

Retrieved on: 
Tuesday, September 12, 2023
Other Professional Services, Software, Data Analytics, Internet, Artificial Intelligence, Professional Services, Technology, Other Technology, B.M.S. College of Engineering, Intelligence, Psychology, DNN, University, College, Phi Lab, Engineering, Harvard University, Linear optics, ICML, Stanford University, University of Cambridge, Ames Research Center, California Institute for Quantitative Biosciences, ML, Harvard Center for Population and Development Studies, Brain, Research, MIT, See, Conference on Neural Information Processing Systems, Associate, University of Notre Dame, Assistant, Science, Biology, International Conference on Learning Representations, Silicon, Tokyo Institute of Technology, Swinburne University of Technology, International Conference on Computer and Information Technology, Machine learning, CBFT, ICLR, International Conference on Machine Learning, Artificial intelligence, Paper, PHI, AI, NTT, Bias, Cornell University, Conference, Medical imaging, California Institute of Technology

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists affiliated with its Physics & Informatics (PHI) Lab have co-authored a paper that proposes a way to overcome bias in deep neural networks (DNNs).
  • “Our PHI Lab scientists and their colleagues have enlarged our understanding of the relatively neglected field of neural network fine-tuning in this notable paper and have proposed an innovative remedy for correcting against bias,” PHI Lab Director Yoshihisa Yamamoto said.
  • In a recent three-month span, top academic journals accepted or published a dozen papers co-authored by PHI Lab scientists.
  • The PHI Lab also has reached joint research agreements with numerous institutions, Harvard University being the most recent.

EQS-News: MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Rituximab, Ruxolitinib, MorphoSys, European Hematology Association, Conference call, Hydroxycarbamide, JAK, ICML, American Society of Clinical Oncology, Lymphoma, Lenalidomide, Cancer, FSE, Incyte, ASCO, BET, Publication, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, EHA, Annual general meeting, Webcast, Society, Conference, Safety, Nursing, Pharmaceutical industry, Beauty salon, Tafasitamab

Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.

Key Points: 
  • Minjuvi royalty revenue of € 2.2 million for sales outside of the U.S. in the second quarter 2023 and € 2.9 million for the first half of 2023.
  • The MorphoSys AG Annual General Meeting on May 17, 2023 re-elected Mr. George Golumbeski, Ph.D., and Mr. Michael Brosnan to the Company’s Supervisory Board.
  • Events After the End of the Second Quarter of 2023:
    On August 1, 2023, Incyte announced the full enrollment of the Phase 3 study inMIND.
  • Total revenues for the second quarter 2023 were € 53.2 million compared to € 59.4 million for the same period in 2022.

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 8, 2023
CCCC, Pharming, G&A, BRAF V600, Patient, Research and development, R, Disease, Multiple myeloma, Drug discovery, Lung cancer, Combination therapy, International Conference on Afghanistan, London (2006), Security (finance), BRD9, FDA, Conference, Safety, Appointment, Roche, BRAF, Medicine, NSCLC, Finance, Controlled Impact Demonstration, Administration, Colorectal cancer, Research, Therapy, Synovial sarcoma, Drug development, CRC, ICML, Clinical trial, Lymphoma, NHL, CNS, Dexamethasone, ASCO, Public expenditure, American Society of Clinical Oncology, Melanoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Biogen, Calico, IND, Mutant

WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Wednesday, August 2, 2023
European Medicines Agency, AACR, B-cell lymphoma, Kite Pharma, CD19, Investment, CD70, RCC, ICML, Multiple myeloma, Infection, American Society of Clinical Oncology, Lymphoma, Anti-CD19 immunotoxin, Cancer, Licensure, CTA, GAAP, FC, Cytopenia, Equity, PFS, UNIVERSAL, EMA, ASCO, Hematological Cancer Research Investment and Education Act, CAR, Incidence, ATM, PIN, 2023 International Conference on Climate Resilient Pakistan, Dor, Cytokine release syndrome, Patient, IVD, Research, American Association for Cancer Research, Therapy, Society, Conference, ORR, News, BCMA, Life insurance, Pharmaceutical industry, Medical imaging, Vaccine

Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.

Key Points: 
  • Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $18.5 million for the second quarter of 2023, which includes $9.7 million of non-cash stock-based compensation expense.
  • Net loss for the second quarter of 2023 was $78.0 million, or $0.53 per share, including non-cash stock-based compensation expense of $16.6 million.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Retrieved on: 
Wednesday, July 26, 2023
ICML, ML, Research, SALT, Student, International Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics, Machine learning, Drug discovery, Recursion, Biology, International Conference on Machine Learning, Artificial intelligence, Conference, Pharmaceutical industry

SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).

Key Points: 
  • SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML).
  • Valence Labs will serve as a machine learning research laboratory focused on developing the next generation of cutting-edge methods and models for drug discovery and consists of the emerging ML research teams at Recursion and the team at Valence Discovery, which Recursion recently acquired.
  • "Recursion believes in the power of open-science initiatives and wants to invest in rising talent and academic collaborations.
  • We are also committed to upholding our legacy of contributing significant datasets and tools for research purposes," said Chris Gibson, Ph.D., Co-founder and CEO of Recursion.